CENTER FOR DRUG EVALUATION AND RESEARCH APPROVAL PACKAGE FOR: APPLICATION NUMBER

NDA 17-820/S-037

Correspondence



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration Rockville, MD 20857

NDA 17-820/S-037

Eli Lilly and Company Attention: Elizabeth C. Sloan, Pharm.D. Lilly Corporate Center Indianapolis, IN 46285

Dear Ms. Sloan:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Dobutrex (dobutamine hydrochloride) Injection

NDA Number: 17-820

Supplement number: S-037

Date of supplement: August 27, 2001

Date of receipt: August 28, 2001

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on October 27, 2001 in accordance with 21 CFR 314.101(a).

All communications concerning this supplement should be addressed as follows:

U.S. Postal Service:

Center for Drug Evaluation and Research Division of Cardio-Renal Drug Products, HFD-110 Attention: Division Document Room 5600 Fishers Lane Rockville, Maryland 20857

Courier/Overnight Mail:

Food and Drug Administration Center for Drug Evaluation and Research Division of Cardio-Renal Drug Products, HFD-110 Attention: Division Document Room 1451 Rockville Pike Rockville, Maryland 20852 If you have any questions, please call:

Mr. Edward Fromm Regulatory Project Manager (301) 594-5313

Sincerely yours,



Natalia A. Morgenstern Chief, Project Management Staff Division of Cardio-Renal Drug Products Office of Drug Evaluation I Center for Drug Evaluation and Research This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Natalia Morgenstern 9/13/01 03:02:08 PM